- Previous Close
4.0100 - Open
4.0800 - Bid 4.0700 x 100
- Ask 4.2100 x 100
- Day's Range
4.0800 - 4.2250 - 52 Week Range
3.8500 - 14.7500 - Volume
105,568 - Avg. Volume
338,600 - Market Cap (intraday)
108.315M - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
-- - EPS (TTM)
-4.4300 - Earnings Date Nov 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.67
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
www.inovio.com127
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: INO
View More
Performance Overview: INO
Trailing total returns as of 2024-11-27, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: INO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: INO
View MoreValuation Measures
Market Cap
104.66M
Enterprise Value
32.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
499.67
Price/Book (mrq)
1.42
Enterprise Value/Revenue
158.80
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.91%
Return on Equity (ttm)
-91.42%
Revenue (ttm)
591.86k
Net Income Avi to Common (ttm)
-121.64M
Diluted EPS (ttm)
-4.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
110.42M
Total Debt/Equity (mrq)
13.42%
Levered Free Cash Flow (ttm)
-70.59M